These findings indicate the ability of anti-CSPG4-(PDD) to significantly restrict tumor growth in vivo to antigen-expressing tumor cells compared with control treatments which included non-specific isotype control ADC, and free antibody plus free payload combined treatments. The gene discussed is CSPG4; the disease is neoplasm.